Interestingly, much evidence is emerging that TGF-β impairs NK and cytotoxic T cell immune recognition of tumors by downregulating the activating receptor NKG2D, hindering tumor removal by these cytotoxic lymphocytes [147,166]. This evidence concerns the gene TGFB1 and neoplasm.